Ticker Details
Summit Therapeutics Inc. Common Stock Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
IPO Date:	April 1, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$11.87B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.28 | 3.79%
Avg Daily Range (30 D):	$0.48 | 2.91%
Avg Daily Range (90 D):	$0.45 | 2.55%

Institutional Daily Volume
Avg Daily Volume:	1.02M
Avg Daily Volume (30 D):	2.54M
Avg Daily Volume (90 D):	2.43M

Trade Size
Avg Trade Size (Sh.):	138
Avg Trade Size (Sh.) (30 D):	79
Avg Trade Size (Sh.) (90 D):	81

Institutional Trades
Total Institutional Trades:	1,452
Avg Institutional Trade:	$3.2M
Avg Institutional Trade (30 D):	$3.17M
Avg Institutional Trade (90 D):	$3.51M
Avg Institutional Trade Volume:	.21M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.49M
Avg Closing Trade (30 D):	$5.58M
Avg Closing Trade (90 D):	$5.41M
Avg Closing Volume:	377.25K

News

Jan 29, 2026 @ 5:28 PM FDA Accepts Summit's Lung Cancer Drug Application,... Source: Vandana Singh

Jan 18, 2026 @ 5:31 PM Trip.com, Regencell Bioscience, And Atlassian Are ... Source: Nabaparna Bhattacharya

Jan 6, 2026 @ 10:12 PM Stock Market Today, Jan. 6: Alumis Shares Surge on... Source: Howard Smith

Dec 5, 2025 @ 6:05 PM Trading Near Its 52-Week Low, Is Summit Therapeuti... Source: David Jagielski

Oct 29, 2025 @ 8:08 PM Why Wall Street Is Backing These 3 Comeback Stocks... Source: Nathan Reiff

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.25	$-.31	$-.76
Diluted EPS	$-1.25	$-.31	$-.76
Revenue
Gross Profit
Net Income / Loss	$-921.62M	$-231.79M	$-565.71M
Operating Income / Loss
Cost of Revenue
Net Cash Flow	$144.76M	$-59.34M	$86.29M
PE Ratio